NCT06818916Recruiting
Hetrombopag in Promoting Platelet Engraftment After Auto-HSCT in Children With Neuroblastoma
Efficacy and Safety of Hetrombopag in Promoting Platelet Engraftment After Autologous Hematopoietic Stem Cell Transplantation in Children With Neuroblastoma
Source: ClinicalTrials.gov · Last updated 3 Dec 2025
Brief summary (registry, in English)
The goal of this clinical trial is to learn if hetrombopag promotes platelet engraftment in neuroblastoma children undergoing autologous hematopoietic stem cell transplantation. The main question it aims to answer is: · Does drug hetrombopag promote platelet engraftment? Participants will take hetrombopag every day for 6 weeks or until platelet \> 100\*10\^9/L.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 20 Jun 2024
- Start date
- 30 Jun 2024
- Primary completion date
- 30 Apr 2027
- Lead sponsor
- Beijing Children's Hospital
- Diseases
- Neuroblastoma, Childhood cancers
- NCT number
- NCT06818916
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 30 Jun 2024 to the primary completion date, 30 Apr 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Have experienced congestive heart failure, arrhythmia, peripheral arteriovenous thrombosis requiring medication treatment within one year prior to enrollment, or have experienced myocardial infarction or cerebral infarction within three months prior to enrollment;
Other illness
- Suffering from thromboembolic diseases;
Lab values
- ALT/AST \> 3 ULN, or TBIL \> 1.5 ULN;
Other
- Other situations that are not suitable for inclusion in the study determined by researchers.
Who the study is looking for
- Age\<18 years old;
- Diagnosed as neuroblastoma;
- ECOG ≤ 2;
- First time receiving autologous hematopoietic stem cell transplantation;
- The subjects or their legal guardians agree to participate and sign the informed consent form.
Age in the registry: - to 18 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Stem Cell Transplantation, Beijing Children's Hospital, Capital Medical University Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.